This Imogam market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the rising incidence of animal bites, the development of innovative therapies, improvements in healthcare infrastructure, increasing healthcare expenditure, and the growing prevalence of immunodeficiency diseases.
The projected growth during the forecast period can be attributed to the rising incidence of rabies, increased international travel, expanding research and development activities, growing vaccination programs, and government initiatives. Key trends expected during this period include the growing adoption of combination therapies, increased demand from the pharmaceutical sector, rising demand for combination vaccines, advancements in blood plasma technology, and greater investments in research and development.
The growing incidence of animal bites is expected to drive the growth of the imogam market. Animal bites occur when individuals are bitten by animals, resulting in injuries that may require medical care. This increase in animal bite incidents can be attributed to factors such as a larger pet population, insufficient animal control, and more frequent human-animal interactions. Imogam is used for immediate post-exposure prophylaxis in individuals bitten by animals, providing passive immunity against rabies until the rabies vaccine takes effect. For instance, a report by Dogster in September 2024 revealed that there were 6,000 dog bite incidents in 2023, with fatalities from dog bites increasing fivefold, rising from 5 in 2022 to 15 in 2023. As a result, the rising number of animal bites is contributing to the growth of the imogam market.
The rise in international travel is another factor expected to accelerate the growth of the imogam market. Increased international travel reflects greater global mobility and tourism, driven by factors such as relaxed restrictions, improved connectivity, and higher disposable incomes. This trend has led to greater exposure to regions where rabies is endemic, increasing the demand for imogam as a crucial post-exposure prophylaxis. For example, according to the Office for National Statistics in May 2024, the number of overseas visitors to the UK grew from 31.2 million in 2022 to 38 million in 2023. This increased international travel, combined with a higher risk of animal bites, is propelling the growth of the imogam market.
The expansion of global healthcare infrastructure is also expected to drive the growth of the imogam market. Healthcare infrastructure encompasses the systems, facilities, and resources necessary to provide healthcare services. Factors such as an aging population, rising chronic disease rates, and technological advancements are accelerating the expansion of healthcare infrastructure. A strong healthcare infrastructure is essential for supporting Imogam Rabies-HT’s use, ensuring proper cold chain maintenance, timely administration, and accessibility for rabies post-exposure prophylaxis. For instance, the Office for National Statistics reported in May 2024 that healthcare expenditure rose by 5.6% from 2022 to 2023, while long-term health and social care expenditure increased by 2.8% in real terms in 2022. The growth of healthcare infrastructure is therefore driving the growth of the imogam market.
The key player in the imogam market is Sanofi SA.
North America was the largest region in the imogam market in 2024. The regions covered in imogam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Imogam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Imogam is the brand name for a human rabies immune globulin (HRIG) product used as part of post-exposure prophylaxis (PEP) to prevent rabies infection following exposure to the rabies virus. It provides passive immunity by delivering antibodies against the virus.
The primary patient demographics for Imogam include pediatric patients, adult patients, and high-risk groups. Pediatric patients are children at risk of rabies due to animal bites or scratches, requiring age-appropriate dosages of rabies vaccines and immune globulin such as Imogam to prevent infection. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for applications such as post-exposure prophylaxis and, in some cases, pre-exposure prophylaxis.
The imogam market research report is one of a series of new reports that provides imogam market statistics, including the imogam industry's global market size, regional shares, competitors with a imogam market share, detailed imogam market segments, market trends and opportunities, and any further data you may need to thrive in the imogam industry. This imogam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The imogam market consists of sales of imogam rabies-HT 150 IU/mL vial, and imogam injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the rising incidence of animal bites, the development of innovative therapies, improvements in healthcare infrastructure, increasing healthcare expenditure, and the growing prevalence of immunodeficiency diseases.
The projected growth during the forecast period can be attributed to the rising incidence of rabies, increased international travel, expanding research and development activities, growing vaccination programs, and government initiatives. Key trends expected during this period include the growing adoption of combination therapies, increased demand from the pharmaceutical sector, rising demand for combination vaccines, advancements in blood plasma technology, and greater investments in research and development.
The growing incidence of animal bites is expected to drive the growth of the imogam market. Animal bites occur when individuals are bitten by animals, resulting in injuries that may require medical care. This increase in animal bite incidents can be attributed to factors such as a larger pet population, insufficient animal control, and more frequent human-animal interactions. Imogam is used for immediate post-exposure prophylaxis in individuals bitten by animals, providing passive immunity against rabies until the rabies vaccine takes effect. For instance, a report by Dogster in September 2024 revealed that there were 6,000 dog bite incidents in 2023, with fatalities from dog bites increasing fivefold, rising from 5 in 2022 to 15 in 2023. As a result, the rising number of animal bites is contributing to the growth of the imogam market.
The rise in international travel is another factor expected to accelerate the growth of the imogam market. Increased international travel reflects greater global mobility and tourism, driven by factors such as relaxed restrictions, improved connectivity, and higher disposable incomes. This trend has led to greater exposure to regions where rabies is endemic, increasing the demand for imogam as a crucial post-exposure prophylaxis. For example, according to the Office for National Statistics in May 2024, the number of overseas visitors to the UK grew from 31.2 million in 2022 to 38 million in 2023. This increased international travel, combined with a higher risk of animal bites, is propelling the growth of the imogam market.
The expansion of global healthcare infrastructure is also expected to drive the growth of the imogam market. Healthcare infrastructure encompasses the systems, facilities, and resources necessary to provide healthcare services. Factors such as an aging population, rising chronic disease rates, and technological advancements are accelerating the expansion of healthcare infrastructure. A strong healthcare infrastructure is essential for supporting Imogam Rabies-HT’s use, ensuring proper cold chain maintenance, timely administration, and accessibility for rabies post-exposure prophylaxis. For instance, the Office for National Statistics reported in May 2024 that healthcare expenditure rose by 5.6% from 2022 to 2023, while long-term health and social care expenditure increased by 2.8% in real terms in 2022. The growth of healthcare infrastructure is therefore driving the growth of the imogam market.
The key player in the imogam market is Sanofi SA.
North America was the largest region in the imogam market in 2024. The regions covered in imogam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Imogam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Imogam is the brand name for a human rabies immune globulin (HRIG) product used as part of post-exposure prophylaxis (PEP) to prevent rabies infection following exposure to the rabies virus. It provides passive immunity by delivering antibodies against the virus.
The primary patient demographics for Imogam include pediatric patients, adult patients, and high-risk groups. Pediatric patients are children at risk of rabies due to animal bites or scratches, requiring age-appropriate dosages of rabies vaccines and immune globulin such as Imogam to prevent infection. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for applications such as post-exposure prophylaxis and, in some cases, pre-exposure prophylaxis.
The imogam market research report is one of a series of new reports that provides imogam market statistics, including the imogam industry's global market size, regional shares, competitors with a imogam market share, detailed imogam market segments, market trends and opportunities, and any further data you may need to thrive in the imogam industry. This imogam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The imogam market consists of sales of imogam rabies-HT 150 IU/mL vial, and imogam injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Imogam Market Characteristics4. Imogam Market Trends and Strategies5. Imogam Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Imogam Pricing Analysis & Forecasts30. Global Imogam Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Imogam Market32. Recent Developments in the Imogam Market
3. Imogam Market Biologic Drug Characteristics
6. Global Imogam Growth Analysis and Strategic Analysis Framework
8. Imogam Market Segmentation
9. Global Imogam Epidemiology of Clinical Indications
10. Imogam Market Regional and Country Analysis
11. Asia-Pacific Imogam Market
12. China Imogam Market
13. India Imogam Market
14. Japan Imogam Market
15. Australia Imogam Market
16. South Korea Imogam Market
17. Western Europe Imogam Market
18. UK Imogam Market
19. Germany Imogam Market
20. France Imogam Market
21. Eastern Europe Imogam Market
22. North America Imogam Market
23. USA Imogam Market
24. Canada Imogam Market
25. South America Imogam Market
26. Middle East Imogam Market
27. Africa Imogam Market
28. Imogam Market Competitive Landscape and Company Profiles
29. Global Imogam Market Pipeline Analysis
33. Imogam Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Imogam Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on imogam market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for imogam? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The imogam market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Patient Demographics: Pediatric Patients; Adult Patients; High-Risk Groups2) by Application: Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis
3) by Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Pharmacies
Key Companies Mentioned: Sanofi SA
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi SA
